Announcement on the Use of Part of the Idle Self-owned Funds for Cash Management

Important Content Indication:

1. Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") will use idle self-owned funds not exceeding 2 billion RMB for cash management, effective for a period not exceeding 12 months.

2. The cash management will focus on low-risk investment products, ensuring that the Company does not engage in high-risk investments.

3. The financial market will be monitored for economic conditions, policy adjustments, and market fluctuations to manage cash effectively.

4. The above matters will be submitted to the 2026 second meeting of the fifth board of directors for approval.

Basic Situation of Cash Management

1. Investment Purpose: To meet the basic cash management needs of the Company and its subsidiaries, optimize the use of funds, and increase investment returns.

2. Investment Amount: Not exceeding 2 billion RMB.

3. Investment Period: The Company will conduct this within 12 months.

4. Source of Funds: Self-owned funds.

5. Investment Methods (Types): Purchasing low-risk financial products from banks and other financial institutions.

6. Investment Status: The cash management will be conducted in accordance with relevant laws and regulations.

7. Key Risk Description: The Company will not engage in high-risk investment mechanisms.

Review Procedures

This matter requires submission to the 2026 second meeting of the fifth board of directors for approval.

Risk Analysis and Control Measures

1. Investment Risks: The cash management will focus on low-risk investment products, but the financial market is subject to economic and policy fluctuations.